Investor Presentaiton slide image

Investor Presentaiton

LOVVOLUS De JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY: NONE OR MILD GLABELLAR LINE RESPONDERS NONE OR MILD GLABELLAR LINES AT MAXIMUM FROWN Investigator + Subject Assessment Pra 40U vs. Daxi 40U Sakura 2 PERCENT OF 90 80 70 60 50 40 g ཞ ཧྨ ➢ ཋ ྴ ༄ ཞ 8 ཤྐ 100 RESPONDERS (%) 30 * 20 Prabot Prabot Daxi Daxi 40U 40U 40U 40U 10 (IA) (SA) (IA) (SA) 0 0 30 60 00 90 120 150 ◆ No prabot data collected between Day 2 and Day 30 *DaxxifyⓇ FDA Prescribing Information (Graph GL1) Carruthers, Plastic Reconstructive Surgery 2020 Jan; 145 (1): 45-58 Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons Baseline Demographics Daxibotulinum Sakura 163.2 Moderate Prabotulinum 40U PII 70.6% Severe 1pt change required 2 pt change required 180 210 240 270 300 330 360 DAYS AFTER TREATMENT 28
View entire presentation